Solaxa Inc. Appoints Kerry Clem as Chief Commercial Officer
Bethesda, MD; August 19, 2024 – Solaxa Inc. announces that Kerry Clem has joined the company in the role of Chief Commercial Officer (CCO). Mr. Clem formerly served as CCO of Acorda Therapeutics, where he led the commercial strategy for Ampyra®(dalfampridine), known chemically as 4-Aminopyradine, approved to help improve walking in adults with Multiple Sclerosis. Kerry held leadership roles at Acorda for over 13 years, rising from VP of Sales to Senior Vice President, Executive Vice President, and then CCO. During that time, Ampyra® amassed more than $3 Billion in cumulative sales.
Prior to joining Acorda Therapeutics, Mr. Clem had held commercial leadership roles at three earlier-stage biotech companies: Allos Therapeutics, Solstice Neurosciences, and Guilford Pharmaceutics.
Solaxa’s Founder and Chief Executive Officer, Christian Walker, noted that “Kerry’s experience in driving the sales of a branded dalfampridine product makes him uniquely qualified to lead Solaxa’s commercial efforts, as we develop new versions of that drug that serve the needs of patients with ataxia and acute nerve injuries. ”
About Solaxa
Solaxa is a clinical-stage biopharmaceutical public benefit corporation developing treatments that restore nerve function in patients with rare neurodegenerative diseases and acute nerve injuries. The company is developing a class of aminopyridine drugs that both detect and treat ion channel dysfunction. Solaxa’s public benefit mission is to advance scientific knowledge and deliver impactful and accessible therapies that improve outcomes for patients worldwide. For more information, visit Solaxa.com.
CONTACT:
Luis Gutierrez, COO
Solaxa Inc.